Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diagnostic Value and Biological Significant of cd71 in Lymphoid Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03720977
Recruitment Status : Not yet recruiting
First Posted : October 26, 2018
Last Update Posted : October 26, 2018
Sponsor:
Information provided by (Responsible Party):
Marwa Aboelim Shafeik, Assiut University

Brief Summary:
CD71 is expressed on activated B and T cells, macrophages, reticulocytes, erythroid precursors, and malignant tissues. , reflecting the requirement for iron in hemoglobin. , CD71 expression is upregulated on immature proliferating cells and low levels on resting mature lymphocytes. In addition to this general function, CD71 appears to play a costimulatory role in T cell activation and receptor for IgA1 antibodies So it is growth receptor that may help in diagnosis of lymphoid disorder and in differentiation of malignant and benign that will be studied investigate CD71 expression in lymphoid disorders and its diagnostic value ,we from collect data patient and do rotune examination

Condition or disease
Lyphoid Disorders cd71

Detailed Description:
  1. Routine investigations for diagnosis:

    • CBC.
    • Bone marrow aspiration morphology.
    • Cytochemistry.
    • Flow cytometry immunophenotyping.
    • Bone marrow biopsy when indicated.
  2. Special investigation is flow cytometry examination of CD71 expression.

sample size calculation ; sample size cases 39 sample size controls 39 total sample size 79 sample will be collected from patient in hospital university ,Data will be analysed by SPSS program


Layout table for study information
Study Type : Observational
Estimated Enrollment : 139 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: Diagnostic Value and Biological Significant of cd71 in Lymphoid Dis Order
Estimated Study Start Date : December 1, 2019
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : December 1, 2020



Primary Outcome Measures :
  1. determin diagnostic value of cd71 in lymphoid disorder [ Time Frame: baseline ]

    Routine investigations for diagnosis:

    CBC. Bone marrow aspiration morphology. Cytochemistry. Flow cytometry immunophenotyping. Bone marrow biopsy when indicated. Special investigation is flow cytometry examination of CD71 expression.

    total sample size 79 person .sample will be collected from patient in hospital university ,Data will be analysed by SPSS program it is growth receptor is expressed on activated B and T cells, macrophages, reticulocytes, erythroid precursors, and malignant tissues




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
confidence level 95 sample size 139
Criteria

Inclusion Criteria:

  • all patients wiil be diagnosed lymphoid disorders

Exclusion Criteria:

  • not present

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03720977


Contacts
Layout table for location contacts
Contact: Marwa Aboelim 01012636292 marwaaboelim@gmail.com
Contact: Tagreed kamal, dr 01002286687

Sponsors and Collaborators
Marwa Aboelim Shafeik
Investigators
Layout table for investigator information
Study Director: Maged Salah, Prof Assiut University .clinical pathologydepartment

Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Marwa Aboelim Shafeik, Principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03720977     History of Changes
Other Study ID Numbers: diagnostic value of cd71
First Posted: October 26, 2018    Key Record Dates
Last Update Posted: October 26, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: immunophenotyping by flow cytometry of cd71

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No